SOHO 2025 | Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma

Now that we’ve had CD19 CAR-T for relapsed/refractory lymphoma for many years now, we’re able to look across a number of different studies including reports globally from, you know, different countries and centers in the US and so on to really understand what are we seeing in real-world practice. And it’s very encouraging to see that overall the response rates are very comparable that we’re seeing globally, US, Europe, and so on, in terms of the response rates, in terms of the side effect profiles, even knowing that a lot of these patients do not necessarily qualify for registrational studies for a variety of reasons for disease status or comorbidities. So those are all very encouraging to see. And it’s also important to start to look at some of those health resource utilizations in terms of hospitalizations, ICU use, and so on. And I think, you know, with the evolving way that we’re managing CAR-T and being able to mitigate some of the more severe severity of the side effects to keep those resource utilizations hopefully more manageable as we expand that and make it more accessible to patients. So those are very important data to continue to keep an eye on, to understand the treatment landscape and the context that CAR-T is offered with the options that we have for aggressive lymphoma. I think overall what we’re seeing is that, you know, despite the concerns with the challenges of CAR-T being a very bespoke kind of therapy, that these can have a way of really rolling out to broader practice.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.